康希諾(06185.HK)吸入式新冠疫苗獲馬來西亞臨床試驗許可
康希諾生物(06185.HK)宣布,旗下吸入用腺病毒載體新冠疫苗「Convidecia Air」已獲得馬來西亞臨床試驗許可,該臨床試驗將評估疫苗作為第二輪加強劑,應對各種變體的安全性和有效性。
康希諾指,Convidecia Air利用與肌注版Convidecia相同的腺病毒載體技術平台,是世界首個吸入式新冠疫苗,可有效誘導黏膜免疫,無需針頭,僅需使用肌肉注射劑量的五分之一,並可以在2°C至8°C之間穩定運輸和儲存,有助於大規模疫苗分發和在全球範圍內建立廣泛的免疫保護。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.